Saturday 17 October 2026
Export PGEN’s income statement to Excel — free account
Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 6,322.7%, EPS grew 166.7% and free cash flow grew 8.73%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.35
0.85
−11.81%
Follow PGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
160.18 | 135.09 | 43.40 | 23.73 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(34.77) | (55.77) | (31.28) | (114.23) | |
P/B ratio |
24.14 | 62.56 | 67.76 | 46.68 | |
Price to Tangible BV |
43.68 | 523.91 | 641.00 | 78.85 | |
EV/Sales |
157.90 | 136.04 | 45.01 | 24.54 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(13.72) | (15.00) | (12.33) | (18.43) | |
EV/FCF |
(13.17) | (14.67) | (12.16) | (18.26) | |
Quick Ratio |
3.81 | 2.74 | 3.93 | 3.76 | |
Current Ratio |
4.04 | 3.09 | 4.82 | 4.58 | |
Net Debt/EBITDA |
0.83 | 0.22 | (7.58) | 2.33 | |
Debt/Assets |
54.24% | 59.92% | 67.46% | 55.13% | |
Debt/Equity |
2.22 | 4.46 | 4.62 | 2.15 | |
Asset Turnover |
0.05 | 0.06 | 0.24 | 0.63 | |
Operating CF/Net income |
0.09 | 1.00 | 5.53 | (0.89) | |
Capex/Depreciation |
(0.70) | (0.03) | (0.24) | (0.31) | |
Interest Coverage |
(38.23) | (7.31) | (2.06) | 7.67 | |
Research and Development Expense of Revenue |
423.58% | 153.12% | 24.25% | 13.25% | |
Selling, General and Administrative Expense of Revenue |
821.05% | 386.53% | 90.53% | 40.47% | |
Intangible Assets out of Total Assets |
0.11 | 0.12 | 0.13 | 0.10 | |
Share Based Compensation of Revenue |
150.17% | 47.38% | 15.19% | 6.51% | |
Graham Net Nets |
0.00 | (0.01) | (0.01) | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(42.25%) | (32.06%) | (30.49%) | (18.07%) | |
Free Cash Flow Yield |
(7.48%) | (6.87%) | (8.53%) | (5.66%) | |
Revenue per Share |
0.01 | 0.01 | 0.07 | 0.15 | |
Operating CF per Share |
(0.09) | (0.07) | (0.12) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.07) | (0.12) | (0.05) | |
Cash per Share |
0.39 | 0.31 | 0.16 | 0.11 | |
Shareholders Equity per Share |
0.14 | 0.07 | 0.06 | 0.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.14 | 0.07 | 0.06 | 0.12 | |
Free Cash Flow |
(29.46) | (23.48) | (44.08) | (18.20) | |
Working Capital |
97.53 | 77.93 | 80.57 | 105.03 | |
Capital Expenditures |
(0.39) | (0.02) | (0.26) | (0.39) | |
Net Current Asset Value |
0.20 | (19.36) | (16.72) | 7.66 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.13 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.91 | 2.76 | 13.88 | 36.31 | |
Average Payables |
5.29 | 7.76 | 2.85 | 4.61 | |
Average Inventory |
7.89 | 4.90 | 7.47 | 10.27 | |
Average Assets |
127.37 | 150.39 | 133.71 | 136.10 | |
Average Common Equity |
48.62 | 29.71 | 3.09 | 3.40 |
Columns are period end dates